<?xml version='1.0' encoding='utf-8'?>
<document id="22971159"><sentence text="Analysis of cytochrome P450 gene polymorphism in a lupus nephritis patient in whom tacrolimus blood concentration was markedly elevated after administration of azole antifungal agents."><entity charOffset="160-165" id="DDI-PubMed.22971159.s1.e0" text="azole" /></sentence><sentence text="Both itraconazole (ITCZ) and voriconazole (VCZ) are potent inhibitors of cytochrome P450 (CYP) 3A, and their effects have been reported to be equal"><entity charOffset="5-17" id="DDI-PubMed.22971159.s2.e0" text="itraconazole" /><entity charOffset="19-23" id="DDI-PubMed.22971159.s2.e1" text="ITCZ" /><entity charOffset="29-41" id="DDI-PubMed.22971159.s2.e2" text="voriconazole" /><entity charOffset="43-46" id="DDI-PubMed.22971159.s2.e3" text="VCZ" /><entity charOffset="12-14" id="DDI-PubMed.22971159.s2.e4" text="azole" /><entity charOffset="36-38" id="DDI-PubMed.22971159.s2.e5" text="azole" /><pair ddi="false" e1="DDI-PubMed.22971159.s2.e0" e2="DDI-PubMed.22971159.s2.e0" /><pair ddi="false" e1="DDI-PubMed.22971159.s2.e0" e2="DDI-PubMed.22971159.s2.e4" /><pair ddi="false" e1="DDI-PubMed.22971159.s2.e0" e2="DDI-PubMed.22971159.s2.e1" /><pair ddi="false" e1="DDI-PubMed.22971159.s2.e0" e2="DDI-PubMed.22971159.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22971159.s2.e0" e2="DDI-PubMed.22971159.s2.e5" /><pair ddi="false" e1="DDI-PubMed.22971159.s2.e0" e2="DDI-PubMed.22971159.s2.e3" /><pair ddi="false" e1="DDI-PubMed.22971159.s2.e4" e2="DDI-PubMed.22971159.s2.e4" /><pair ddi="false" e1="DDI-PubMed.22971159.s2.e4" e2="DDI-PubMed.22971159.s2.e1" /><pair ddi="false" e1="DDI-PubMed.22971159.s2.e4" e2="DDI-PubMed.22971159.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22971159.s2.e4" e2="DDI-PubMed.22971159.s2.e5" /><pair ddi="false" e1="DDI-PubMed.22971159.s2.e4" e2="DDI-PubMed.22971159.s2.e3" /><pair ddi="false" e1="DDI-PubMed.22971159.s2.e1" e2="DDI-PubMed.22971159.s2.e1" /><pair ddi="false" e1="DDI-PubMed.22971159.s2.e1" e2="DDI-PubMed.22971159.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22971159.s2.e1" e2="DDI-PubMed.22971159.s2.e5" /><pair ddi="false" e1="DDI-PubMed.22971159.s2.e1" e2="DDI-PubMed.22971159.s2.e3" /><pair ddi="false" e1="DDI-PubMed.22971159.s2.e2" e2="DDI-PubMed.22971159.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22971159.s2.e2" e2="DDI-PubMed.22971159.s2.e5" /><pair ddi="false" e1="DDI-PubMed.22971159.s2.e2" e2="DDI-PubMed.22971159.s2.e3" /><pair ddi="false" e1="DDI-PubMed.22971159.s2.e5" e2="DDI-PubMed.22971159.s2.e5" /><pair ddi="false" e1="DDI-PubMed.22971159.s2.e5" e2="DDI-PubMed.22971159.s2.e3" /></sentence><sentence text=" However, ITCZ is metabolized by CYP3A, whereas VCZ is mainly metabolized by CYP2C9 and CYP2C19 and only partially by CYP3A"><entity charOffset="10-14" id="DDI-PubMed.22971159.s3.e0" text="ITCZ" /><entity charOffset="48-52" id="DDI-PubMed.22971159.s3.e1" text="VCZ" /><pair ddi="false" e1="DDI-PubMed.22971159.s3.e0" e2="DDI-PubMed.22971159.s3.e0" /><pair ddi="false" e1="DDI-PubMed.22971159.s3.e0" e2="DDI-PubMed.22971159.s3.e1" /></sentence><sentence text=" We experienced the case of a patient who showed a 5-fold increase in trough levels of tacrolimus (FK) level after switching from ITCZ to VCZ"><entity charOffset="87-97" id="DDI-PubMed.22971159.s4.e0" text="tacrolimus" /><entity charOffset="130-139" id="DDI-PubMed.22971159.s4.e1" text="ITCZ" /><entity charOffset="138-147" id="DDI-PubMed.22971159.s4.e2" text="VCZ" /><pair ddi="false" e1="DDI-PubMed.22971159.s4.e0" e2="DDI-PubMed.22971159.s4.e0" /><pair ddi="false" e1="DDI-PubMed.22971159.s4.e0" e2="DDI-PubMed.22971159.s4.e1" /><pair ddi="false" e1="DDI-PubMed.22971159.s4.e0" e2="DDI-PubMed.22971159.s4.e2" /><pair ddi="false" e1="DDI-PubMed.22971159.s4.e1" e2="DDI-PubMed.22971159.s4.e1" /><pair ddi="false" e1="DDI-PubMed.22971159.s4.e1" e2="DDI-PubMed.22971159.s4.e2" /></sentence><sentence text=" Our objective is to discuss the mechanism of the increase drug-drug interaction in terms of serum concentration of the azole drugs and patient pharmacogenomics"><entity charOffset="120-125" id="DDI-PubMed.22971159.s5.e0" text="azole" /></sentence><sentence text="" /><sentence text="A 53-year-old woman was treated with FK (1 mg/day) for lupus nephritis" /><sentence text=" Because fungal infection was suspected, she received ITCZ (100 mg/day)"><entity charOffset="54-58" id="DDI-PubMed.22971159.s8.e0" text="ITCZ" /></sentence><sentence text=" When ITCZ was replaced with VCZ (400 mg/day), the blood concentration of FK increased markedly from 6·1 to 34·2 ng/mL"><entity charOffset="29-32" id="DDI-PubMed.22971159.s9.e0" text="VCZ" /><entity charOffset="6-8" id="DDI-PubMed.22971159.s9.e1" text="ITCZ" /><pair ddi="false" e1="DDI-PubMed.22971159.s9.e1" e2="DDI-PubMed.22971159.s9.e1" /><pair ddi="false" e1="DDI-PubMed.22971159.s9.e1" e2="DDI-PubMed.22971159.s9.e0" /></sentence><sentence text=" During coadministration with FK, the levels of ITCZ and VCZ were 135·5 ng/mL and 5·5 μg/mL, respectively, with the VCZ level around 3-fold higher than the previously reported level (1·4-1·8 μg/mL)"><entity charOffset="30-32" id="DDI-PubMed.22971159.s10.e0" text="FK" /><entity charOffset="48-49" id="DDI-PubMed.22971159.s10.e1" text="ITCZ" /><entity charOffset="57-58" id="DDI-PubMed.22971159.s10.e2" text="VCZ" /><entity charOffset="116-117" id="DDI-PubMed.22971159.s10.e3" text="VCZ" /><pair ddi="false" e1="DDI-PubMed.22971159.s10.e0" e2="DDI-PubMed.22971159.s10.e0" /><pair ddi="false" e1="DDI-PubMed.22971159.s10.e0" e2="DDI-PubMed.22971159.s10.e1" /><pair ddi="false" e1="DDI-PubMed.22971159.s10.e0" e2="DDI-PubMed.22971159.s10.e2" /><pair ddi="false" e1="DDI-PubMed.22971159.s10.e0" e2="DDI-PubMed.22971159.s10.e3" /><pair ddi="false" e1="DDI-PubMed.22971159.s10.e1" e2="DDI-PubMed.22971159.s10.e1" /><pair ddi="false" e1="DDI-PubMed.22971159.s10.e1" e2="DDI-PubMed.22971159.s10.e2" /><pair ddi="false" e1="DDI-PubMed.22971159.s10.e1" e2="DDI-PubMed.22971159.s10.e3" /><pair ddi="false" e1="DDI-PubMed.22971159.s10.e2" e2="DDI-PubMed.22971159.s10.e2" /><pair ddi="false" e1="DDI-PubMed.22971159.s10.e2" e2="DDI-PubMed.22971159.s10.e3" /></sentence><sentence text=" Her CYP genotypes were CYP2C19*1/*2, CYP3A4*1/*1 and CYP3A5*3/*3" /><sentence text="" /><sentence text="The patient was a CYP2C19 intermediate metabolizer (IM) and deficient in CYP3A5" /><sentence text=" The increase in plasma VCZ level appears to have been at least in part, associated with the CYP2C19 IM phenotype"><entity charOffset="24-26" id="DDI-PubMed.22971159.s14.e0" text="VCZ" /></sentence><sentence text=" One possible explanation for the marked increase in blood FK concentration was increased inhibition of CYP3A because of the impaired metabolism and subsequent increased plasma concentration of VCZ"><entity charOffset="194-196" id="DDI-PubMed.22971159.s15.e0" text="VCZ" /><entity charOffset="59-61" id="DDI-PubMed.22971159.s15.e1" text="FK" /><pair ddi="false" e1="DDI-PubMed.22971159.s15.e1" e2="DDI-PubMed.22971159.s15.e1" /><pair ddi="false" e1="DDI-PubMed.22971159.s15.e1" e2="DDI-PubMed.22971159.s15.e0" /></sentence><sentence text=" This case shows that the severity of drug interactions may be influenced by metabolic gene polymorphism" /><sentence text="" /></document>